P04.6. pCR and ctDNA in SCIENCE: A Phase III Trial of Neoadjuvant Immunotherapy in Resectable LA-ESCC

Clicks: 1
ID: 325703
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #92 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background The optimal neoadjuvant strategy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) remains controversial. Although chemotherapy combined with PD-1 blockade has demonstrated promising activity, it is unclear whether adding radiotherapy further enhances pathological response and long-term outcomes without compromising surgical feasibility. The phase III SCIENCE trial was designed to compare neoadjuvant chemotherapy plus sintilimab, chemoradiotherapy plus sintilimab, and chemoradiotherapy alone in resectable LA-ESCC. The study evaluates pathological complete response and event-free survival as dual primary endpoints and explores circulating tumor DNA (ctDNA) as an early biomarker of treatment response. Methods SCIENCE is a multicentre, randomized, phase III trial conducted at seven centers in China. Treatment-naive patients with histologically confirmed thoracic ESCC (cT1N2–3M0 or cT2–4aN0–3M0; AJCC/UICC 8th edition) were randomized (1:1:1) to neoadjuvant chemotherapy plus sintilimab (A), chemoradiotherapy plus sintilimab (B), or chemoradiotherapy alone (C). Surgery was scheduled 6–8 weeks after neoadjuvant therapy. Dual primary endpoints were pathological complete response (pCR) and event-free survival (EFS). Longitudinal ctDNA was assessed using a personalized tumor-informed assay at baseline, during therapy, and preoperatively. pCR will be compared using the Chi-square test and logistic regression, and EFS using log-rank and Cox models. The overall two-sided type I error is controlled at 0.05 (0.02 for pCR; 0.03 for EFS). Data cutoff is January 19, 2026. Results Between November 2022 and August 2025, 307 patients were randomized to Group A (n=100), Group B (n=103), or Group C (n=104). Most were male (88.3%) with stage III disease (81.4%); all achieved R0 resection. pCR rates were 18.0% (A), 57.3% (B), and 49.0% (C). Compared with A, pCR was significantly higher in B (OR 6.1, 95% CI 3.3–11.9; p<0.0001) and C (OR 4.4, 95% CI 2.3–8.5; p<0.0001). Among 92 evaluable patients for ctDNA analysis, detectability declined from 96.7% at baseline to 48.9% preoperatively. Preoperative ctDNA positivity was higher in A (78.6%) versus B (40.0%) and C (32.4%) (p<0.001). ctDNA clearance was strongly associated with pCR (62.2% vs 9.1%, p<0.001) and increased stepwise across response categories. Conclusion In resectable locally advanced ESCC, the addition of immunotherapy to chemoradiotherapy significantly improved pathological complete response compared with chemotherapy plus immunotherapy, without compromising surgical feasibility. Chemoradiotherapy-based regimens achieved superior pathological responses and deeper ctDNA clearance, supporting intensified multimodality approaches. Preoperative ctDNA dynamics strongly correlated with pathological response, highlighting its potential as an early biomarker of treatment efficacy. These findings provide prospective phase III evidence to inform optimal neoadjuvant strategies and support ctDNA-guided response assessment in LA-ESCC.
Reference Key
openalex_W7203929504 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Xuefeng Leng
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.004
URL
https://doi.org/10.1093/dote/doag077.004
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.